Kim C J, Puleo C, Letson G D, Reintgen D
Cultaneous Oncology Program, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Fla. 33612-9497, USA.
Cancer Control. 2001 May-Jun;8(3):269-73. doi: 10.1177/107327480100800307.
The treatment options available for extremity sarcomas are amputation or limb-sparing surgery with radiation, which may incur significant morbidity and body disfigurement. Hyperthermic isolated limb perfusion (HILP) may be an attractive option in extremity sarcomas for unresectable lesions to preserve limb function and maintain quality of life.
We report the outcomes of 5 patients who underwent HILP for unresectable primary or recurrent extremity sarcomas from 1994 to 2000 at our institution.
All patients had initial complete clinical responses to HILP, and the limb was salvaged in 4 of the 5 patients. Complications included chronic lymphedema, neuropathic pain, and prolonged wound healing.
HILP with melphalan is a safe and effective treatment option for selected patients with locally advanced and unresectable extremity sarcomas. The response rates are high, with limb salvage occurring in most patients. Further studies of larger groups of patients are warranted.
肢体肉瘤的治疗选择包括截肢或保肢手术联合放疗，这可能会导致严重的发病率和身体畸形。对于不可切除的病变，高温隔离肢体灌注（HILP）可能是肢体肉瘤中一种有吸引力的选择，以保留肢体功能并维持生活质量。
我们报告了1994年至2000年在我们机构对5例不可切除的原发性或复发性肢体肉瘤患者进行高温隔离肢体灌注（HILP）的结果。
所有患者对HILP最初均有完全的临床反应，5例患者中有4例肢体得以保留。并发症包括慢性淋巴水肿、神经性疼痛和伤口愈合延长。
美法仑高温隔离肢体灌注（HILP）是局部晚期且不可切除的肢体肉瘤特定患者的一种安全有效的治疗选择。缓解率很高，大多数患者实现了肢体保留。有必要对更大规模的患者群体进行进一步研究。
